Nothing Special   »   [go: up one dir, main page]

SG11202005696YA - Substituted indole compounds useful as tlr inhibitors - Google Patents

Substituted indole compounds useful as tlr inhibitors

Info

Publication number
SG11202005696YA
SG11202005696YA SG11202005696YA SG11202005696YA SG11202005696YA SG 11202005696Y A SG11202005696Y A SG 11202005696YA SG 11202005696Y A SG11202005696Y A SG 11202005696YA SG 11202005696Y A SG11202005696Y A SG 11202005696YA SG 11202005696Y A SG11202005696Y A SG 11202005696YA
Authority
SG
Singapore
Prior art keywords
compounds useful
substituted indole
indole compounds
tlr inhibitors
tlr
Prior art date
Application number
SG11202005696YA
Inventor
Alaric J Dyckman
Dharmpal S Dodd
Christopher P Mussari
John L Gilmore
Tasir Shamsul Haque
Trevor C Sherwood
Brian K Whiteley
Shoshana L Posy
Sreekantha Ratna Kumar
Laxman Pasunoori
Srinivasan Kunchithapatham Duraisamy
Subramanya Hegde
Rushith Kumar Anumula
Pitani Veera Venkata Srinivas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202005696YA publication Critical patent/SG11202005696YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202005696YA 2017-12-19 2018-12-18 Substituted indole compounds useful as tlr inhibitors SG11202005696YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607472P 2017-12-19 2017-12-19
PCT/US2018/066149 WO2019126113A1 (en) 2017-12-19 2018-12-18 Substituted indole compounds useful as tlr inhibitors

Publications (1)

Publication Number Publication Date
SG11202005696YA true SG11202005696YA (en) 2020-07-29

Family

ID=65003586

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005696YA SG11202005696YA (en) 2017-12-19 2018-12-18 Substituted indole compounds useful as tlr inhibitors

Country Status (14)

Country Link
US (1) US11878975B2 (en)
EP (1) EP3728225B1 (en)
JP (1) JP7291145B2 (en)
KR (1) KR20200101402A (en)
CN (1) CN111491930B (en)
AU (1) AU2018390820A1 (en)
BR (1) BR112020012084A2 (en)
CA (1) CA3085590A1 (en)
EA (1) EA202091474A1 (en)
ES (1) ES2932361T3 (en)
IL (1) IL275356A (en)
MX (1) MX2020005462A (en)
SG (1) SG11202005696YA (en)
WO (1) WO2019126113A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX2020005513A (en) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors.
JP7291707B2 (en) 2017-12-20 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー Aryl- and heteroaryl-substituted indole compounds
JP7328977B2 (en) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー Novel sulfone compounds and derivatives for the treatment and prevention of viral infections
CN112313228A (en) 2018-06-12 2021-02-02 豪夫迈·罗氏有限公司 Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
JP2022505827A (en) 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー Substituted indole dimer compound
CN114126713B (en) * 2019-05-09 2023-12-08 百时美施贵宝公司 Substituted benzimidazolone compounds
US20240076280A1 (en) 2019-10-04 2024-03-07 Bristol-Myers Squibb Company Substituted carbazole compounds
US20230116201A1 (en) * 2020-01-30 2023-04-13 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
TW202241419A (en) * 2020-12-22 2022-11-01 美商基利科學股份有限公司 6-substituted indole compounds
CR20230478A (en) 2021-04-16 2023-11-30 Gilead Sciences Inc Thienopyrrole compounds.
TWI849499B (en) 2021-09-10 2024-07-21 美商基利科學股份有限公司 Thienopyrrole compounds
MX2024009441A (en) * 2022-02-18 2024-08-14 Bristol Myers Squibb Co Substituted imidazopyridinyl compounds useful as inhibitors of tlr9.
CN114591339B (en) * 2022-05-10 2022-08-02 上海维申医药有限公司 Toll-like receptor inhibitor and preparation and application thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CA2355249A1 (en) 1998-12-18 2000-06-22 Jason M. Hataye Protease inhibitors
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
NZ533958A (en) 2002-01-07 2007-09-28 Eisai Co Ltd Deazapurines and uses thereof
US7008958B2 (en) * 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
EP1633694A4 (en) 2003-06-05 2007-03-14 Merck & Co Inc Substituted indoles and a process for preparing substituted indoles
MXPA05013922A (en) 2003-06-20 2006-02-24 Coley Pharm Group Inc Small molecule toll-like receptor (tlr) antagonists.
UA90477C2 (en) * 2004-07-14 2010-05-11 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Methods for treating hepatitis c (variants)
AU2006324144A1 (en) 2005-01-28 2007-08-02 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009532501A (en) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド Compounds for diseases and disorders
DE102006033109A1 (en) 2006-07-18 2008-01-31 Grünenthal GmbH Substituted heteroaryl derivatives
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
US20100197657A1 (en) * 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
EP2350032B1 (en) * 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
TWI462920B (en) 2009-06-26 2014-12-01 葛萊伯格有限公司 Novel compound useful for the treatment of degenerative and inflammatory diseases
PL2453895T3 (en) 2009-07-16 2018-10-31 Mallinckrodt Llc (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
KR20120068947A (en) 2009-09-24 2012-06-27 에프. 호프만-라 로슈 아게 Indole derivatives as crac modulators
MX2012004792A (en) 2009-10-22 2013-02-01 Vertex Pharma Compositions for treatment of cystic fibrosis and other chronic diseases.
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
MX346387B (en) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators.
CN106518851A (en) 2011-01-12 2017-03-22 帆德制药股份有限公司 Substituted benzoazepines as toll-like receptor modulators
US9359361B2 (en) 2011-06-01 2016-06-07 Janus Biotherapeutics, Inc. Immune system modulators
CA2837207A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013010904A1 (en) 2011-07-15 2013-01-24 Janssen Pharmaceuticals, Inc. Novel substituted indole derivatives as gamma secretase modulators
IN2014KN00948A (en) 2011-10-04 2015-08-21 Janus Biotherapeutics Inc
TWI619704B (en) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 Carboxylic acid compounds
JO3407B1 (en) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
EP3057964B1 (en) 2013-10-14 2019-12-04 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
EP3080124A1 (en) 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
CN106661034B (en) 2014-08-15 2019-11-29 正大天晴药业集团股份有限公司 Pyrrolopyrimidine compounds as TLR7 agonist
EP3398948A3 (en) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
EP3072891A1 (en) 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) * 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
CN109923108B (en) * 2016-09-09 2022-04-29 百时美施贵宝公司 Pyridyl-substituted indole compounds
US11130756B2 (en) 2017-08-04 2021-09-28 Bristol-Myers Squibb Company [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds
KR102651947B1 (en) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Substituted indole compounds useful as inhibitors of TLR7/8/9
ES2945435T3 (en) 2017-11-14 2023-07-03 Bristol Myers Squibb Co Substituted indole compounds

Also Published As

Publication number Publication date
CA3085590A1 (en) 2019-06-27
IL275356A (en) 2020-07-30
US20200308172A1 (en) 2020-10-01
EA202091474A1 (en) 2020-11-18
EP3728225A1 (en) 2020-10-28
CN111491930A (en) 2020-08-04
MX2020005462A (en) 2020-09-07
KR20200101402A (en) 2020-08-27
ES2932361T3 (en) 2023-01-18
US11878975B2 (en) 2024-01-23
EP3728225B1 (en) 2022-11-09
CN111491930B (en) 2023-09-26
BR112020012084A2 (en) 2020-11-24
WO2019126113A1 (en) 2019-06-27
JP7291145B2 (en) 2023-06-14
AU2018390820A1 (en) 2020-08-06
JP2021506889A (en) 2021-02-22

Similar Documents

Publication Publication Date Title
IL275356A (en) Substituted indole compounds useful as tlr inhibitors
IL275353A (en) Amide substituted indole compounds useful as tlr inhibitors
ME03740B (en) Indole carboxamide compounds useful as kinase inhibitors
IL275504A (en) Amino indole compounds useful as tlr inhibitors
HK1249905A1 (en) Heterocyclic compounds as lsd1 inhibitors
LT3704120T (en) Heterocyclic compounds as prmt5 inhibitors
PL3371190T3 (en) Heterocyclic compounds as pi3k-gamma inhibitors
HUE059716T2 (en) Compounds useful as ret inhibitors
IL264785B (en) Condensed thiophene derivatives useful as napi-iib inhibitors
IL274821A (en) Compounds as mpges-1 inhibitors
GB201613945D0 (en) Compounds useful as kinase inhibitors